Gastrointestinal Stromal Tumor (GIST)
作者： Lesly A. Dossett , Nipun B. Merchant
DOI: 10.1007/978-1-4939-1423-4_28
关键词: Cancer research 、 Stromal tumor 、 Tyrosine-kinase inhibitor 、 Sarcoma 、 Tyrosine kinase 、 GiST 、 Imatinib 、 Interstitial cell of Cajal 、 Medicine 、 PDGFRA
摘要: Gastrointestinal stromal tumors (GISTs) are the most common sarcoma of GI tract and account for 1–3 % all malignancies. GISTs arise from interstitial cells Cajal, an intestinal pacemaker cell located in around myenteric plexus. They typically stomach (65–70 %) or small intestine (25–45 %). An important immunohistochemical marker is KIT, a membrane receptor with tyrosine kinase activity that present (80–95 Some (5–7 have mutation platelet-derived growth factor alpha (PDGFRA) instead. Several factors including tumor site, size greater than 5 cm, mitoses per 50 high-power field predict aggressive behavior recurrence. The treatment localized resection. Systemic chemotherapy radiation ineffective. inhibitor imatinib improves progression-free survival patients metastatic disease, its use adjuvant neoadjuvant settings increasingly common. Many ultimately develop resistance, these patients, dose escalation another recommended.
springer.com
core.ac.uk
elsevier.com
sci-hub.st 参考文章(32)
H. Joensuu, M. Eriksson, J. Hatrmann, K. Sundby Hall, J. Schutte, A. Reichardt, M. Schlemmer, E. Wardelmann, G. Ramadori, S. Al-Batran, B. E. Nilsson, O. Monge, R. Kallio, M. Sarlomo-Rikala, P. Bono, M. Leinonen, P. Hohenberger, T. Alvegard, P. Reichardt, Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO). Journal of Clinical Oncology. ,vol. 29, ,(2011) , 10.1200/JCO.2011.29.15_SUPPL.LBA1
Ihor Pidhorecky, Richard T. Cheney, William G. Kraybill, John F. Gibbs, Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Annals of Surgical Oncology. ,vol. 7, pp. 705- 712 ,(2000) , 10.1007/S10434-000-0705-6
Heikki Joensuu, Christopher Fletcher, Sasa Dimitrijevic, Sandra Silberman, Peter Roberts, George Demetri, Management of malignant gastrointestinal stromal tumours. Lancet Oncology. ,vol. 3, pp. 655- 664 ,(2002) , 10.1016/S1470-2045(02)00899-9
Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Jörg T. Hartmann, Daniel Pink, Jochen Schütte, Giuliano Ramadori, Peter Hohenberger, Justus Duyster, Salah-Eddin Al-Batran, Marcus Schlemmer, Sebastian Bauer, Eva Wardelmann, Maarit Sarlomo-Rikala, Bengt Nilsson, Harri Sihto, Odd R. Monge, Petri Bono, Raija Kallio, Aki Vehtari, Mika Leinonen, Thor Alvegård, Peter Reichardt, One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor JAMA. ,vol. 307, pp. 1265- 1272 ,(2012) , 10.1001/JAMA.2012.347
Bengt Nilsson, Per Bümming, Jeanne M. Meis-Kindblom, Anders Odén, Aydin Dortok, Bengt Gustavsson, Katarzyna Sablinska, Lars-Gunnar Kindblom, Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden. Cancer. ,vol. 103, pp. 821- 829 ,(2005) , 10.1002/CNCR.20862
Pelle Gustafson, Soft tissue sarcoma : epidemiology and prognosis in 508 patients Acta Orthopaedica Scandinavica. ,vol. 65, pp. 2- 31 ,(1994) , 10.3109/17453679409153928
Christopher D.M. Fletcher, Heikki Joensuu, George D. Demetri, Margaret von Mehren, Charles D. Blanke, Annick D. Van den Abbeele, Burton Eisenberg, Peter J. Roberts, Michael C. Heinrich, David A. Tuveson, Samuel Singer, Milos Janicek, Jonathan A. Fletcher, Stuart G. Silverman, Sandra L. Silberman, Renaud Capdeville, Beate Kiese, Bin Peng, Sasa Dimitrijevic, Brian J. Druker, Christopher Corless, Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. The New England Journal of Medicine. ,vol. 347, pp. 472- 480 ,(2002) , 10.1056/NEJMOA020461
H. Joensuu, Gastrointestinal stromal tumor (GIST) Annals of Oncology. ,vol. 17, ,(2006) , 10.1093/ANNONC/MDL274
Heikki Joensuu, Aki Vehtari, Jaakko Riihimäki, Toshirou Nishida, Sonja E Steigen, Peter Brabec, Lukas Plank, Bengt Nilsson, Claudia Cirilli, Chiara Braconi, Andrea Bordoni, Magnus K Magnusson, Zdenek Linke, Jozef Sufliarsky, Massimo Federico, Jon G Jonasson, Angelo Paolo Dei Tos, Piotr Rutkowski, None, Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts Lancet Oncology. ,vol. 13, pp. 265- 274 ,(2012) , 10.1016/S1470-2045(11)70299-6
Maria Debiec-Rychter, Raf Sciot, Axel Le Cesne, Marcus Schlemmer, Peter Hohenberger, Allan T. van Oosterom, Jean-Yves Blay, Serge Leyvraz, Michel Stul, Paolo G. Casali, John Zalcberg, Jaap Verweij, Martine Van Glabbeke, Anne Hagemeijer, Ian Judson, KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours European Journal of Cancer. ,vol. 42, pp. 1093- 1103 ,(2006) , 10.1016/J.EJCA.2006.01.030